| Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator S Lain, JJ Hollick, J Campbell, OD Staples, M Higgins, M Aoubala, ... Cancer cell 13 (5), 454-463, 2008 | 555 | 2008 |
| 2, 6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK) JJ Hollick, BT Golding, IR Hardcastle, N Martin, C Richardson, ... Bioorganic & medicinal chemistry letters 13 (18), 3083-3086, 2003 | 148 | 2003 |
| Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition … JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ... Journal of medicinal chemistry 50 (8), 1958-1972, 2007 | 91 | 2007 |
| Pilot screening programme for small molecule activators of p53 RG Berkson, JJ Hollick, NJ Westwood, JA Woods, DP Lane, S Lain International journal of cancer 115 (5), 701-710, 2005 | 63 | 2005 |
| Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins AR McCarthy, L Pirrie, JJ Hollick, S Ronseaux, J Campbell, M Higgins, ... Bioorganic & medicinal chemistry 20 (5), 1779-1793, 2012 | 61 | 2012 |
| P53 activating compounds S Lain, DP Lane, MJR Stark, AR McCarthy, JJ Hollick, NJ Westwood US Patent 8,501,991, 2013 | 21 | 2013 |
| Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen OD Staples, JJ Hollick, J Campbell, M Higgins, AR McCarthy, V Appleyard, ... Cell Cycle 7 (21), 3417-3427, 2008 | 15 | 2008 |
| The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screen AR McCarthy, JJ Hollick, NJ Westwood Seminars in cancer biology 20 (1), 40-45, 2010 | 13 | 2010 |
| Synthesis and biological evaluation of functionalised tetrahydro-β-carboline analogues as inhibitors of Toxoplasma gondii invasion JGA Walton, S Patterson, G Liu, JD Haraldsen, JJ Hollick, AMZ Slawin, ... Organic & Biomolecular Chemistry 7 (15), 3049-3060, 2009 | 13 | 2009 |
| Pyrimidine derivatives as protein kinase inhibitors JJ Hollick, SD Jones, CJ Flynn, MG Thomas US Patent 8,563,542, 2013 | 7 | 2013 |
| Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia S Moureau, E Pohler, K Kroboth, C Saladino, C MacKay, J Hollick, ... European Journal of Cancer 1 (69), S117, 2016 | 5 | 2016 |
| Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization S Frame, C Aspinall, R O'Neil, J Hollick, S Taylor, T Hupp, D Blake, ... Cancer Research 72, 2012 | 4 | 2012 |
| Application of combinatorial chemistry for the identification of pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase JJ Hollick, BT Golding, RJ Griffin, IR Hardcastle, JJJ Leahy, N Martin, ... 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, 2002 | 1 | 2002 |
| The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations S Moureau, C MacKay, C Saladino, E Pohler, K Kroboth, J Hollick, ... Cancer Research 77 (13_Supplement), 4178-4178, 2017 | | 2017 |
| (") TargetDBR"-A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate DNA repair … JJ Hollick, L Abriola, F Bono, D Hegan, P Klingbeil, Y Liu, R Sundaram, ... MOLECULAR CANCER RESEARCH 15, 2017 | | 2017 |
| Abstract B25:“TargetDBR”—A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate … JJ Hollick, L Abriola, F Bono, D Hegan, P Klingbeil, Y Liu, R Sundaram, ... Molecular Cancer Research 15 (4_Supplement), B25-B25, 2017 | | 2017 |
| Pochodne pirymidyny jako inhibitory kinaz białkowych JJ Hollick, SD Jones, CJ Flynn, MG Thomas | | 2016 |
| Pyrimidine derivatives as protein kinase inhibitors JJ Hollick, SD Jones, CJ Flynn, MG Thomas US Patent 9,493,471, 2016 | | 2016 |
| Derivados de pirimidina como inhibidores de proteína cinasa JJ Hollick, SD Jones, CJ Flynn, MG Thomas | | 2016 |
| P53 activating compounds S Lain, DP Lane, MJR Stark, AR McCarthy, JJ Hollick, NJ Westwood US Patent 9,120,765, 2015 | | 2015 |
